Evidence map›Paper›PMID 33500248›Full record

Observational studyCancer research2021

A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis.

Priyanka Kulkarni, Pritha Dasgupta, Yutaka Hashimoto, Marisa Shiina, Varahram Shahryari, Z Laura Tabatabai, Soichiro Yamamura, Yuichiro Tanaka, Sharanjot Saini, Rajvir Dahiya and 1 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. The potential role of miR-155 in the tumorigenesis of cervical cancer.Frontiers in cell and developmental biology · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Priyanka Kulkarni *Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Pritha Dasgupta *Department of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.ORCID 0000-0002-9283-9326
Yutaka HashimotoDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Marisa ShiinaDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Varahram ShahryariDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Z Laura TabatabaiDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Soichiro YamamuraDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Yuichiro TanakaDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California.
Sharanjot SainiMedical College of Georgia, Augusta University, Augusta, Georgia.
Rajvir DahiyaDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California. Shahana.Majid@ucsf.edu rdahiya@ucsf.edu.
Shahana MajidDepartment of Urology, Veterans Affairs Medical Center, San Francisco and University of California San Francisco, San Francisco, California. Shahana.Majid@ucsf.edu rdahiya@ucsf.edu.
San Francisco VA Medical Center · USAugusta University · US

Funding

Genistein and chemotherapy of kidney cancerR01CA196848 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YAMAMURA, SOICHIRO · 2016 to 2020
$1.7M
Molecular biomarkers for kidney cancer prognosis using non-coding RNAsR01CA199694 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI TANAKA, YUICHIRO · 2016 to 2020
$1.7M
Regulation of c-Myc/HIF pathway in the management of kidney cancerI01BX001123 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI DAHIYA, RAJVIR · 2012 to 2020
–
BLR&D Research Career Scientist Award ApplicationIK6BX004473 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI DAHIYA, RAJVIR · 2019 to 2021
–
BLRD VA I01 BX001123BLRD VA IK6 BX004473NCI NIH HHS R01 CA196848NCI NIH HHS R01 CA199694
6 · The paper itself

Abstract

Metastasis is the leading cause of mortality from kidney cancer, and understanding the underlying mechanism of this event will provide better strategies for its management. Here we investigated the biological, functional, and clinical significance of lncTCL6 and its interacting miR-155 in clear cell renal cell carcinoma (ccRCC). We employed a comprehensive approach to investigate the lncTCL6-miR-155-Src/Akt-mediated epithelial-to-mesenchymal transition (EMT) pathway as a novel regulatory mechanism in ccRCC progression. Expression analyses revealed that lncTCL6 is downregulated in ccRCC compared with normal tissues. Overexpression of lncTCL6 in ccRCC cell lines impaired their oncogenic functions, such as cell proliferation and migration/invasion, and induced cell-cycle arrest and apoptosis; conversely, depletion of lncTCL6 rescued these phenotypic effects. Furthermore, lncTCL6 directly interacted with miR-155. Unlike lncTCL6, miR-155 was overexpressed in ccRCC. Stable knockdown of miR-155 phenocopied the effects of lncTCL6 overexpression. Conversely, reconstitution of miR-155 and suppression of lncTCL6 in noncancerous renal cell HK2 induced tumorigenic characteristics. Patients with higher expression of lncTCL6 and lower expression of miR-155 had better survival probability. When overexpressed, lncTCL6 recruited STAU1 and mediated decay of Src mRNA, followed by a marked downregulation of an integrated network of Src target genes involved in migration, invasion, and EMT. However, the interaction between miR-155 and lncTCL6 attenuated the regulatory role of lncTCL6 on Src-mediated EMT. In conclusion, this study is the first report documenting the lncTCL6-miR155-Src/Akt/EMT network as a novel regulatory mechanism in aggressive ccRCC and a promising therapeutic target to inhibit renal cancer. SIGNIFICANCE: This study's investigation of noncoding RNA interactions in renal cell carcinoma identify miRNA-155-lncRNA TCL6-mediated regulation of the Src-Akt-EMT network as a novel mechanism of disease progression and metastasis.

Indexed as

Gene Expression Regulation, NeoplasticAgedAnimalsCarcinogenesisCarcinoma, Renal CellCell Line, TumorDown-RegulationEpithelial-Mesenchymal TransitionFollow-Up StudiesGene Knockdown TechniquesHumansKaplan-Meier EstimateKidneyKidney NeoplasmsMaleMiceAKT1 protein, humanlong noncoding RNA TCL6, humanMicroRNAsMIRN155 microRNA, humanProto-Oncogene Proteins c-aktRNA, Long Noncodingsrc-Family Kinases

Identifiers

PMID33500248
PMCPMC7969457
OpenAlexW3122794633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.